O'PKA ARTERIAL GIPERTENZIYASIDA 6 DAQIQALIK YURISH TESTI VA KARDIOPULMONAL TESTNING QIYOSIY TAHLILI
;
https://doi.org/10.5281/zenodo.20588152;
o'pka arterial gipertenziyasi, 6 daqiqalik yurish testi, kardiopulmonal yurish testi, qiyosiy tahlil, xavf stratifikatsiyasi, prognoz.Abstrak
O'pka arterial gipertenziyasi (OAG) bemorlarda jismoniy tolerantlikni baholashda 6 daqiqalik yurish testi (6DYT) va kardiopulmonal yurish testi (KPYT) ikki asosiy yondashuv hisoblanadi. Ushbu maqolada ikkala testning diagnostik aniqlik, prognostik qiymat, amaliy qulaylik va klinik qo'llanilish sohalari bo'yicha qiyosiy tahlili o'tkazildi. 6DYT arzon, keng mavjud va OAG xavf stratifikatsiyasida standartlashtirilgan parametr bo'lsa-da, u KPYT ga nisbatan cheklangan fiziologik ma'lumot beradi. KPYT esa ko'proq patofiziyologik ma'lumot, yuqori prognostik aniqlik va qo'shimcha tashxis imkoniyatlarini taqdim etadi. Ikki test bir-birini to'ldiruvchi vosita sifatida ko'rilishi va kombinatsiyada qo'llanilishi tavsiya etiladi. O'pka arterial gipertenziyasi bo'lgan bemorlarni umr davomiyligini va hayot sifatini yaxshilash choralarini ishlab chiqishda 6DYT va KPYT ma'lumotlaridan keng ko'lamda foydalanishni talab etadi. ROC tahlili asosida KPYT ko'rsatkichlari (AUC taxminan 0,84) prognozni bashorat qilishda 6DYT ga (AUC taxminan 0,71) nisbatan statistik jihatdan ahamiyatli ustunlik ko'rsatadi. Biroq 6DYT kundalik hayot faoliyatini yaxshiroq aks ettiradi. Tavsiyalarga ko'ra, 6DYT har 3–6 oyda rutinada, KPYT esa murakkab klinik qarorlar qabul qilishda qo'shimcha vosita sifatida ishlatilishi maqsadga muvofiq.Iqtiboslar
Galie N., Humbert M., Vachiery J.L. et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618–3731.
Miyamoto S., Nagaya N., Satoh T. et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 2000;161(2):487–492.
ATS Committee. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.
ATS/ACCP Statement on Cardiopulmonary Exercise Testing. Am J Respir Crit Care Med. 2003;167(2):211–277.
Sun X.G., Hansen J.E., Oudiz R.J., Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001;104(4):429–435.
Kylhammar D., Kjellstrom B., Hjalmarsson C. et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175–4181.
Wensel R., Opitz C.F., Anker S.D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319–324.
Humbert M., Sitbon O., Yaici A. et al. Survival in incident and prevalent cohort of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549–555.
Barst R.J., McGoon M., McLaughlin V. et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41(12):2119–2125.
Benza R.L., Miller D.P., Barst R.J. et al. An evaluation of long-term survival from time of diagnosis in PAH from the REVEAL Registry. Chest. 2012;142(2):448–456.
##submission.downloads##
Nashr qilingan
Nashr
Bo'lim
Litsenziya
##submission.copyrightStatement##
##submission.license.cc.by4.footer##Iqtibos keltirish tartibi
